Recurrence of lesions of Crohn's disease of the ileum within 1 year after so-called curative resection was well documented by endoscopy in 73%-93% of cases. This study investigated the efficacy of mesalamine in reduction of endoscopic recurrence after surgery. In a double-blind,multicenter clinical trial,87 patients were treated with 3 g/day mesalamine (Pentasa) or with placebo within 1 month after surgery. After 12 months of treatment,severity of endoscopic lesions was recorded with a five-point score; when it was not possible to reach the anastomosis by endoscopy,a barium enema was performed.
Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group / Brignola, C; Cottone, M; Pera, A; Ardizzone, S; Scribano, Ml; De Franchis, R; D'Arienzo, Agesilao; D'Albasio, G; Pennestri, D.. - In: GASTROENTEROLOGY. - ISSN 0892-1601. - ELETTRONICO. - 108:2(1995), pp. 345-349.
Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group.
D'ARIENZO, AGESILAO;
1995
Abstract
Recurrence of lesions of Crohn's disease of the ileum within 1 year after so-called curative resection was well documented by endoscopy in 73%-93% of cases. This study investigated the efficacy of mesalamine in reduction of endoscopic recurrence after surgery. In a double-blind,multicenter clinical trial,87 patients were treated with 3 g/day mesalamine (Pentasa) or with placebo within 1 month after surgery. After 12 months of treatment,severity of endoscopic lesions was recorded with a five-point score; when it was not possible to reach the anastomosis by endoscopy,a barium enema was performed.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
